STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium
STC-15 is the first METTL3 inhibitor to enter clinical development
Presentation to highlight updated interim results, demonstrating that STC-15 was well tolerated, and clinical activity observed across pharmacologically active dose range in advanced cancer patients
9 October 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it will be presenting a poster on the ongoing Phase 1 trial with its lead METTL3 RNA methyltransferase inhibitor, STC-15, at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held in Barcelona, Spain, from 23-25 October 2024.
